Table 2.
List of genes highly differentially expressed (q ≤ %) in PAH lungs relative to both normal controls and PH secondary to IPF
Gene Symbol | Description | Ingenuity Canonical Pathway | Log2 Fold Change (PAH vs. Control, PAH vs. PH Secondary to IPF) |
---|---|---|---|
Cell-to-cell signaling and interaction | |||
IL16 | Interleukin 16 | −1.9, −2.4 | |
PF4 | Platelet factor 4 | 2.1, 4.01 | |
CEACAM3 | Carcinoembryonic antigen-related cell adhesion molecule 3 | −1.6, −1.7 | |
GP1BA | Glycoprotein Ib (platelet), α-polypeptide | 1.5, 3.6 | |
ITGAV | Integrin, αV | Integrin signaling | −2.01, −1.5 |
C5AR1 | Complement component 5a receptor 1 | Complement system | 1.8, 2.4 |
F2RL3 | Coagulation factor II (thrombin) receptor-like 3 | 2.1, 3.2 | |
CYBB | Cytochrome b558, β-polypeptide | Leukocyte extravasation signaling | 2.5, 2.8 |
GREM1 | Gremlin 1 | −1.5, −2.1 | |
TNC | Tenascin C | −2, −2 | |
LAMA3 | Laminin, α3 | 1.6, 1.5 | |
GJB1 | Gap junction protein, β1 | 1.6, 1.9 | |
MSN | Moesin | Leukocyte extravasation signaling | 1.9, 2.5 |
RAP1GAP | RAP1 GTPase activating protein | cAMP-mediated signaling | 1.6, 1.8 |
EPHA3 | EPH receptor A3 | Ephrin Receptor signaling | −1.6, −2.1 |
CD46 | CD46 molecule, complement regulatory protein | Complement system | −2.2, −2.8 |
CHAT | Choline acetyltransferase | Glycerophospholipid metabolism | 1.9, 1.3 |
Cardiovascular system development and function | |||
CASQ2 | Calsequestrin 2 | Calcium signaling | −1.8, −2.1 |
SFRS1 | Splicing factor, arginine/serine-rich 1 | −1.6, −1.5 | |
PLN | Phospholamban | Nitric oxide signaling in the cardiovascular system | −1.7, −2.9 |
PPP2CA | Protein phosphatase 2 (formerly 2A), catalytic subunit, α-isoform | β-Adrenergic pathway | −1.9, −1.1 |
SLC8A1 | Solute carrier family 8, member 1 | Calcium signaling | 1.8, 1.7 |
TPM1 | Tropomyosin 1 | Calcium signaling | 2.2, 1.9 |
PDE4D | Phosphodiesterase 4D | cAMP-mediated signaling | 1.8, 1.7 |
Cardiovascular disease | |||
CA1 | Carbonic anhydrase I | Nitrogen metabolism | 1.7, 2.1 |
KCNMB3 | Potassium large-conductance calcium-activated channel, subfamily M β-member 3 | −1.6, −1.4 | |
P2RY1 | Purinergic receptor P2Y | G protein-coupled receptor signaling | 2.1, 2.8 |
Cellular assembly and organization | |||
NRTN | Neurturin | Ephrin receptor signaling | 2.3, 1.3 |
KALRN | Kalirin | −1.7, −1.3 | |
CHL1 | Cell adhesion molecule with homology to L1CAM | −3.0, −2.9 | |
HK2 | Hexokinase 2 | Aminosugars metabolism | 2.6, 2.4 |
HIPK2 | Homeodomain interacting protein kinase 2 | p53 signaling | 1.5, 1.1 |
FGD4 | FYVE, RhoGEF, and PH domain containing 4 | 1.5, 2.0 | |
MPP7 | Membrane protein, palmitoylated 7 | 2.1, 2.6 | |
GABBR1 | γ-Aminobutyric acid (GABA) B receptor, 1 | GABA receptor signaling | −1.6, −1.3 |
NCOA2 | Nuclear receptor coactivator 2 | Estrogen receptor signaling | −1.9, −1.2 |
Cellular growth and proliferation | |||
SLC1A2 | Solute carrier family 1, member 2 | Glutamate receptor signaling | 1.7, 1.8 |
IL7R | Interleukin 7 receptor | 1.5, 1.7 | |
Cell cycle | |||
CCNG2 | Interleukin 7 receptor | −1.8, −2.0 | |
UBA3 | Ubiquitin-like modifier activating enzyme 3 | −1.7, −1.4 | |
Cellular compromise and cellular development | |||
SLC20A1 | Solute carrier family 20, member 1 | −1.7, −1.4 | |
RAP1GAP | RAP1 GTPase activating protein | cAMP-mediated signaling | 1.6, 1.1 |
IL33 | Interleukin 33 | −1.9, −1.3 |